Patents Assigned to Signal Pharmaceuticals LLC
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
    Publication number: 20140315848
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a cytidine analog to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventor: HEATHER RAYMON
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
    Publication number: 20140314752
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: ANTONIA LOPEZ-GIRONA, KRISTEN MAE HEGE, RAJESH CHOPRA
  • PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
    Publication number: 20140315908
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Anil Menon, Darshan K. Parikh, Dora Visky, Matthew Michael Kreilein, Nathan Boersen, Thomas Lee, Ying Li, Jean Xu, Xiaozhang Liang, William Wei-Hwa Leong, Benjamin Cohen
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
    Publication number: 20140314751
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: KRISTEN MAE HEGE, RAJESH CHOPRA
  • TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES
    Publication number: 20140315907
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: HEATHER RAYMON, SHUICHAN XU, ANTONIA LOPEZ-GIRONA, TOSHIYA TSUJI, KRISTEN MAE HEGE
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
    Publication number: 20140314753
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a 5-Substituted Quinazolinone Compound to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC.
    Inventors: KRISTEN MAE HEGE, RAJESH CHOPRA
  • TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES
    Publication number: 20140314673
    Abstract: Provided herein are methods for treating or preventing head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression, comprising administering an effective amount of a dihydropyrazino-pyrazine to a patient having head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: HEATHER RAYMON, SHUICHAN XU, TOSHIYA TSUJI, KRISTEN MAE HEGE
  • TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES
    Publication number: 20140314674
    Abstract: Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: HEATHER RAYMON, KRISTEN MAE HEGE
  • METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY
    Publication number: 20140315900
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: HEATHER RAYMON, TOSHIYA TSUJI, RAMA K. NARLA, KRISTEN MAE HEGE
  • HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH
    Publication number: 20140206697
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 24, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: STEVEN CLAREEN, VERONIQUE PLANTEVIN-KRENITSKY, MOORTHY PALANKI, YOSHITAKA SATOH
  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20140200207
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 17, 2014
    Applicant: Signal Pharmaceutical LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Mehran Fallah Moghaddam, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning
  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20140200206
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 17, 2014
    Applicant: Signal Pharmaceutical LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Mehran Fallah Moghaddam, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning
  • METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS
    Publication number: 20140155593
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury
  • INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY
    Publication number: 20140113905
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 24, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20140113904
    Abstract: Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 24, 2014
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Deborah Mortensen, Heather Raymon, Rama K. Narla, Kristen Mae Hege, Kimberly Elizabeth Fultz, Toshiya Tsuji
  • PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE
    Publication number: 20140093566
    Abstract: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.
    Type: Application
    Filed: November 8, 2013
    Publication date: April 3, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: Sreenivas S. Bhat, Xiaozhong Liang, Anthony Tutino, Anthony Joseph Frank
  • Methods of synthesis and purification of heteroaryl compounds
    Patent number: 8686135
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 1, 2014
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Anthony Jokiel, Juan Antonio Gamboa, Philip Pye, William Wei-Hwa Leong, Anusuya Choudhury
  • Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
    Patent number: 8680076
    Abstract: Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing scleroderma, keloids, UV injury, or sunburn, and methods for improving or preventing scar formation.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: March 25, 2014
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Brian Edwin Cathers, Kristen Lee Jensen-Pergakes, Heather Raymon, Weilin Xie, Jaman May Maroni
  • Pharmaceutical formulations of a substituted diaminopurine
    Patent number: 8603527
    Abstract: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: December 10, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Sreenivas S. Bhat, Xiaozhong Liang, Anthony Tutino, Anthony Joseph Frank
  • PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
    Publication number: 20130289271
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: June 26, 2013
    Publication date: October 31, 2013
    Applicant: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Sophie Perrin-Ninkovic, Roy L. Harris, John Sapienza, Graziella I. Shevlin, Patrick Papa, Branden Lee, Garrick Packard, Lida Tehrani, Jingjing Zhao, Jennifer Riggs, Jason Parnes, Deborah Mortensen, Weiming Xu, Loui Madakamutil, Kimberly Elizabeth Fultz, Rama Narla, Sabita Sankar, Jan Elsner